Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

The global number of patients with diabetes mellitus (DM) has been growing steadily. Over the past decade, the number has more than doubled and reached 371 million people by 2013. [1] In most cases it is type 2 diabetes. The dangerous consequences of DM include micro- and macrovascular complications...

Full description

Bibliographic Details

Published in:	Медицинский совет
Main Authors:	T. B. Morgunova, V. V. Fadeev
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2015-12-01
Subjects:	сахарный диабет сахароснижающие препараты гликемия инкретин глюкагоноподобный пептид-1 випидия diabetes mellitus hypoglycemic agents glycemia incretin glucagon-like peptide-1 vipidia
Online Access:	https://www.med-sovet.pro/jour/article/view/122